- Home
- MPB vs ATXS Comparison
MPB vs ATXS Comparison
Compare MPB & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- ATXS
- Stock Information
- Founded
- MPB 1868
- ATXS 2008
- Country
- MPB United States
- ATXS United States
- Employees
- MPB N/A
- ATXS N/A
- Industry
- MPB Major Banks
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- MPB Finance
- ATXS Health Care
- Exchange
- MPB Nasdaq
- ATXS Nasdaq
- Market Cap
- MPB 525.0M
- ATXS 516.4M
- IPO Year
- MPB N/A
- ATXS 2015
- Fundamental
- Price
- MPB $29.78
- ATXS $7.57
- Analyst Decision
- MPB Buy
- ATXS Strong Buy
- Analyst Count
- MPB 2
- ATXS 5
- Target Price
- MPB $36.00
- ATXS $25.60
- AVG Volume (30 Days)
- MPB 67.9K
- ATXS 340.8K
- Earning Date
- MPB 01-28-2025
- ATXS 03-03-2025
- Dividend Yield
- MPB 2.68%
- ATXS N/A
- EPS Growth
- MPB 14.41
- ATXS N/A
- EPS
- MPB 2.91
- ATXS N/A
- Revenue
- MPB $173,416,000.00
- ATXS N/A
- Revenue This Year
- MPB N/A
- ATXS N/A
- Revenue Next Year
- MPB $19.26
- ATXS N/A
- P/E Ratio
- MPB $10.26
- ATXS N/A
- Revenue Growth
- MPB 4.93
- ATXS N/A
- 52 Week Low
- MPB $19.20
- ATXS $7.16
- 52 Week High
- MPB $33.87
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- MPB 55.01
- ATXS 31.15
- Support Level
- MPB $28.48
- ATXS $7.45
- Resistance Level
- MPB $29.25
- ATXS $7.95
- Average True Range (ATR)
- MPB 0.70
- ATXS 0.40
- MACD
- MPB 0.23
- ATXS -0.06
- Stochastic Oscillator
- MPB 93.36
- ATXS 20.30
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.